{"filing":{"accession_number":"0001104659-26-093782","cik":"0000894158","ticker":"TOVX","company_name":"Theriva Biologics, Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"tm2622636d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465926093782/tm2622636d1_8k.htm"},"events":[{"id":26912,"run_id":24479,"accession_number":"0001104659-26-093782","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) disclosing financial results including operating expenses, net loss, cash position, and operational highlights. The filing explicitly states \"issued a press release that included financial information for its quarter ended June 30, 2026\" with the press release attached as Exhibit 99.1, which is the standard format for earnings disclosures under Item 2.02. The disclosure includes condensed consolidated balance sheets and statements of operations showing a net loss of $3.2 million for Q2 2026 and cash position of $11.3 million, material information for investors assessing the company's financial condition.","company_name":"Theriva Biologics, Inc.","ticker":"TOVX","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28209,"accession_number":"0001104659-26-093782","item_number":"2.02","item_title":"Results of Operations and Financial","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) disclosing financial results including operating expenses, net loss, cash position, and operational highlights. The filing explicitly states \"issued a press release that included financial information for its quarter ended June 30, 2026\" with the press release attached as Exhibit 99.1, which is the standard format for earnings disclosures under Item 2.02. The disclosure includes condensed consolidated balance sheets and statements of operations showing a net loss of $3.2 million for Q2 2026 and cash position of $11.3 million, material information for investors assessing the company's financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T12:11:47.930540+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28209,"accession_number":"0001104659-26-093782","item_number":"2.02","item_title":"Results of Operations and Financial","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) disclosing financial results including operating expenses, net loss, cash position, and operational highlights. The filing explicitly states \"issued a press release that included financial information for its quarter ended June 30, 2026\" with the press release attached as Exhibit 99.1, which is the standard format for earnings disclosures under Item 2.02. The disclosure includes condensed consolidated balance sheets and statements of operations showing a net loss of $3.2 million for Q2 2026 and cash position of $11.3 million, material information for investors assessing the company's financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T12:11:47.930540+00:00","company_name":"Theriva Biologics, Inc.","ticker":"TOVX","filing_date":"2026-08-11"}]}